Florian Kuehn1, Gunnar Loske2, Leif Schiffmann3, Michael Gock4, Ernst Klar4. 1. Department of General, Thoracic, Vascular and Transplantation Surgery, University of Rostock, Schillingallee 35, 18057, Rostock, Germany. florian_kuehn@gmx.net. 2. Department for General, Abdominal, Thoracic and Vascular Surgery, Katholisches Marienkrankenhaus Hamburg gGmbH, 22087, Hamburg, Germany. 3. Westmecklenburg Hospital - Helene von Buelow, 19230, Hagenow, Ludwigslust, Germany. 4. Department of General, Thoracic, Vascular and Transplantation Surgery, University of Rostock, Schillingallee 35, 18057, Rostock, Germany.
Abstract
BACKGROUND: Postoperative, iatrogenic or spontaneous upper gastrointestinal defects result in significant morbidity and mortality of the patients. In the last few years, endoscopic vacuum therapy (EVT) has been recognized as a new promising method for repairing upper gastrointestinal defects of different etiology. However, probably due to insufficient data and no commercially available system for EVT of the upper gastrointestinal tract, until the end of 2014, covering of esophageal defects with self-expanding metal stents (SEMS) were still the mainstay of endoscopic therapy. The aim of this article is to review the data available about EVT for various upper gastrointestinal defects. METHODS: A selective literature search was conducted in Medline and PubMed (2007-2016), taking into account all the published case series and case reports reporting on the use of EVT in the management of upper gastrointestinal defects. RESULTS: EVT works through intracorporal application of negative pressure at the defect zone with an electronic controlled vacuum device along a polyurethane sponge drainage. This results in closure of the esophageal defect and internal drainage of the septic focus, simultaneously. Compared to stenting, EVT enables regular viewing of wound conditions with control of the septic focus and adjustment of therapy. Moreover, endoscopical negative pressure is applicable in all esophageal regions (cricopharygeal, tubular, gastroesophageal junction) and in anastomotic anatomic variants. EVT can be used solely as a definite treatment or as a complimentary therapy combined with operative revision. In total, there are published data of more than 200 patients with upper gastrointestinal defects treated with EVT, showing succes rates from 70-100%. CONCLUSION: The available data indicate that EVT is feasible, safe and effective with good short-term and long-term clinical outcomes in the damage control of upper GI-tract leaks. Still, a prospective multi-center study has to be conducted to proof the definite benefit of EVT for patients with esophageal defects.
BACKGROUND: Postoperative, iatrogenic or spontaneous upper gastrointestinal defects result in significant morbidity and mortality of the patients. In the last few years, endoscopic vacuum therapy (EVT) has been recognized as a new promising method for repairing upper gastrointestinal defects of different etiology. However, probably due to insufficient data and no commercially available system for EVT of the upper gastrointestinal tract, until the end of 2014, covering of esophageal defects with self-expanding metal stents (SEMS) were still the mainstay of endoscopic therapy. The aim of this article is to review the data available about EVT for various upper gastrointestinal defects. METHODS: A selective literature search was conducted in Medline and PubMed (2007-2016), taking into account all the published case series and case reports reporting on the use of EVT in the management of upper gastrointestinal defects. RESULTS:EVT works through intracorporal application of negative pressure at the defect zone with an electronic controlled vacuum device along a polyurethane sponge drainage. This results in closure of the esophageal defect and internal drainage of the septic focus, simultaneously. Compared to stenting, EVT enables regular viewing of wound conditions with control of the septic focus and adjustment of therapy. Moreover, endoscopical negative pressure is applicable in all esophageal regions (cricopharygeal, tubular, gastroesophageal junction) and in anastomotic anatomic variants. EVT can be used solely as a definite treatment or as a complimentary therapy combined with operative revision. In total, there are published data of more than 200 patients with upper gastrointestinal defects treated with EVT, showing succes rates from 70-100%. CONCLUSION: The available data indicate that EVT is feasible, safe and effective with good short-term and long-term clinical outcomes in the damage control of upper GI-tract leaks. Still, a prospective multi-center study has to be conducted to proof the definite benefit of EVT for patients with esophageal defects.
Authors: Mike G Laukoetter; Rudolf Mennigen; Philipp A Neumann; Sameer Dhayat; Gabriele Horst; Daniel Palmes; Norbert Senninger; Thorsten Vowinkel Journal: Surg Endosc Date: 2016-10-05 Impact factor: 4.584
Authors: Gregorios A Paspatis; Jean-Marc Dumonceau; Marc Barthet; Søren Meisner; Alessandro Repici; Brian P Saunders; Antonios Vezakis; Jean Michel Gonzalez; Stine Ydegaard Turino; Zacharias P Tsiamoulos; Paul Fockens; Cesare Hassan Journal: Endoscopy Date: 2014-07-21 Impact factor: 10.093
Authors: Jonathan Loeck; Hans-Jürgen von Lücken; Adrian Münscher; Christian Theodor Müller; Gunnar Loske Journal: Eur Arch Otorhinolaryngol Date: 2021-03-14 Impact factor: 2.503
Authors: Sameer A Dhayat; Rosanna Schacht; Rudolf Mennigen; Daniel Palmes; Thomas Vogel; Thorsten Vowinkel; Norbert Senninger; Mike Georg Laukoetter Journal: J Gastrointest Surg Date: 2018-11-14 Impact factor: 3.452
Authors: Marc Bludau; Hans F Fuchs; Till Herbold; Martin K H Maus; Hakan Alakus; Felix Popp; Jessica M Leers; Christiane J Bruns; Arnulf H Hölscher; Wolfgang Schröder; Seung-Hun Chon Journal: Surg Endosc Date: 2017-12-07 Impact factor: 4.584